BioSpace News Archive

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Juan Andres, Chief Technical Operations and Quality Officer, has been elected to the National Academy of Engineering, broadly recognized as one of the highest acknowledgments of achievement in the field of engineering.

Arena Pharmaceuticals, Inc. will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets.

Seagen Inc. reported financial results for the fourth quarter and year ended December 31, 2021.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today it will build on the content of its completed 510(k) application and pursue the De Novo pathway for its TAEUS System, which is intended to characterize fatty liver tissue as a means to non-invasively assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD).

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 64,050 shares of the Company’s common stock at an exercise price per share of $30.30, which was the closing price on February 8, 2022, and restricted stock units to acquire a total of 2,025 shares of the Company’s common stock.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced that the third quarter financial results of the 2022 fiscal year will be released on Monday, February 14, 2022.

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended December 31, 2021.

Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, announced the completion of a $21M venture equity financing.

ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, announced that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference.

Acral lentiginous melanoma is a form of skin cancer that disproportionately affects minority groups.